Minireview

British Journal of Cancer (2006) 94, 1355–1360. doi:10.1038/sj.bjc.6603120 www.bjcancer.com
Published online 25 April 2006

Targeting lymphangiogenesis to prevent tumour metastasis

M G Achen1, G B Mann2 and S A Stacker1

  1. 1Ludwig Institute for Cancer Research, Post Office Box 2008 Royal Melbourne Hospital, Victoria 3050, Australia
  2. 2Department of Surgery, The Royal Melbourne Hospital, University of Melbourne, Parkville 3050, Victoria, Australia

Correspondence: Associate Professor MG Achen or Associate Professor SA Stacker, E-mails: Marc.achen@ludwig.edu.au, Steven.stacker@ludwig.edu.au

Received 27 January 2006; Revised 20 March 2006; Accepted 29 March 2006; Published online 25 April 2006.

Top

Abstract

Recent studies involving animal models of cancer and clinicopathological analyses of human tumours suggest that the growth of lymphatic vessels (lymphangiogenesis) in or nearby tumours is associated with the metastatic spread of cancer. The best validated molecular signalling system for tumour lymphangiogenesis involves the secreted proteins vascular endothelial growth factor-C (VEGF-C) and VEGF-D that induce growth of lymphatic vessels via activation of VEGF receptor-3 (VEGFR-3) localised on the surface of lymphatic endothelial cells. In this review, we discuss the evidence supporting a role for this signalling system in the spread of cancer and potential approaches for blocking this system to prevent tumour metastasis.

Keywords:

inhibitor, lymphatic vessel, VEGF-C, VEGF-D, VEGFR-3

Top

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated

NEWS AND VIEWS

From angiogenesis to lymphangiogenesis

Nature Medicine News and Views (01 Feb 2001)

The fatal detachment

Nature Cell Biology News and Views (01 Jul 2001)